U.S. sites begin trials of Bracco's Vueway contrast agent

2020 10 16 23 20 7849 Bracco2 Rsna 2018 400

Contrast agent developer Bracco Diagnostics said that Wellstar Health System is among the first in the U.S. to begin trials of its Vueway (gadopiclenol) macrocyclic gadolinium-based contrast agent (GBCA) for MRI.

Bracco received U.S. Food and Drug Administration (FDA) approval for gadopiclenol in September 2022 for use with MRI in adults and pediatric patients aged two years and older to detect and visualize lesions in the central nervous system and the body.

The GBCA was developed jointly by Bracco and Guerbet under a collaboration agreement signed in December 2021. Both companies have the right to market the contrast agent under their own trade names.

Page 1 of 604
Next Page